Sha Tin, Hong Kong Clinical Trials

A listing of Sha Tin, Hong Kong clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor …

Eisai Trail Site #16
 (5.7 away) Contact site
  • 2 views
  • 06 Apr, 2021
  • +16 other locations
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects with advanced liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma). Phase II is …

Prince of Wales Hospital
 (4.4 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • 1 location
Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies

The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.

The Angeles Clinic
 (7198.3 away) Contact site
  • 2 views
  • 14 Apr, 2021
  • +8 other locations
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

cancer
pralsetinib
RET
systemic therapy
blu-667
The Chinese University of Hong Kong
 (4.4 away) Contact site
  • 1632 views
  • 15 May, 2021
  • +92 other locations
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy …

cancer
ROS1
solid tumor
Hong Kong United Oncology Centre PHASE 2
 (4.2 away) Contact site
  • 338 views
  • 05 Feb, 2021
  • +131 other locations
A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

cancer
RET
kidney function test
systemic therapy
measurable disease
Prince of Wales Hospital
 (5.8 away) Contact site
  • 1244 views
  • 20 Jun, 2021
  • +158 other locations
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations …

cancer
cancer chemotherapy
c-MET
solid tumors
measurable disease
Hong Kong United Oncology Centre
 (4.4 away) Contact site
  • 144 views
  • 29 May, 2021
  • +94 other locations
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study …

cancer
renal function tests
kidney function test
fibrosarcoma
experimental drug
Hong Kong United Oncology Centre
 (4.2 away) Contact site
  • 1310 views
  • 21 Jun, 2021
  • +78 other locations
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) …

b-cell lymphoma
cancer
hodgkin's disease
measurable disease
Novartis Investigative Site
 (5.8 away) Contact site
  • 132 views
  • 14 Jun, 2021
  • +16 other locations
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part …

squamous cell carcinoma
metastasis
gastric cancer
breast cancer
lymphoma
Queen Mary Hospital
 (8.4 away) Contact site
  • 50 views
  • 01 Feb, 2021
  • +30 other locations